HIGHLIGHTS
- who: Nathalie Rufer from the University of Massachusetts Medical School, USA have published the research work: Identifying individual T cell receptors of optimal avidity for tumor antigens, in the Journal: (JOURNAL) of 03/09/2015
- what: Limitations of laboratory techniques are the major reasons why this is infrequently done. The authors report the feasibility and usefulness of TCR-pMHC structural avidity assessment by NTAmers of naturally occurring polyclonal T_cell responses, allowing the identification and selection of rare high-avidity cytotoxic T_cells from patients for cancer therapy.
- future: In the near future more neoantigens . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.